12:00 AM
 | 
Feb 11, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Abilify aripiprazole regulatory update

Otsuka said the European Commission approved a label expansion for Abilify aripiprazole to include treatment of moderate to severe manic episodes in bipolar I disorder in adolescents ages >=13 for up to 12 weeks. Abilify is approved in the EU...

Read the full 177 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >